Balyasny Asset Management LLC Cassava Sciences Inc Transaction History

Balyasny Asset Management LLC

  • $58 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
SELL
$12.64 - $30.11 $1.36 Million - $3.25 Million
-107,789 Reduced 71.91%
42,099 $947,000
Q3 2023

Nov 14, 2023
BUY
$16.64 - $25.32 $1.98 Million - $3.02 Million
119,169 Added 387.93%
149,888 $2.49 Million
Q2 2023

Aug 14, 2023
BUY
$21.59 - $27.88 $460,428 - $594,568
21,326 Added 227.04%
30,719 $753,000
Q1 2023

May 15, 2023
BUY
$23.46 - $36.44 $220,359 - $342,280
9,393 New
9,393 $226,000
Q3 2022

Nov 14, 2022
BUY
$16.33 - $51.06 $110,766 - $346,339
6,783 New
6,783 $283,000

Others Institutions Holding SAVA

# of Institutions
207
Shares Held
14M
Call Options Held
2.98M
Put Options Held
6.57M
View Full List

About CASSAVA SCIENCES INC

SAVA Quotes by TradingView
  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $110M
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Balyasny Asset Management LLC Portfolio

Follow Balyasny Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email